Genetic variants of human N-acetyltransferase 1 (NAT1) are associated with cancer and birth defects. N-and O-acetyltransferase catalytic activities, Michaelis-Menten kinetic constants (K m and V max ) and steady-state expression levels of NAT1-specific mRNA and protein were determined for the reference NAT1*4 and variant human NAT1 haplotypes possessing single nucleotide polymorphisms (SNPs) in the open reading frame. Although none of the SNPs caused a significant effect on steady-state levels of NAT1-specific mRNA, C97T(R33stop), C190T(R64W), C559T (R187stop) and A752T(D251V) each reduced NAT1 protein level and/or N-and O-acetyltransferase catalytic activities to levels below detection. G560A(R187Q) substantially reduced NAT1 protein level and catalytic activities and increased substrate K m . The G445A(V149I), G459A(synonymous) and T640G(S214A) haplotype present in NAT1*11 significantly (Po0.05) increased NAT1 protein level and catalytic activity. Neither T21G(synonymous), T402C(synonymous), A613G(M205V), T777C(synonymous), G781A(E261K) nor A787G(I263V) significantly affected K m , catalytic activity, mRNA or protein level. These results suggest heterogeneity among slow NAT1 acetylator phenotypes.
Introduction
Human N-acetyltransferase 1 (NAT1) and 2 (NAT2) catalyze the transfer of an acetyl group from acetyl coenzyme A (AcCoA) to exocyclic amine groups of many arylamine amine drugs and carcinogens. 1, 2 Following N-hydroxylation, NAT1 and NAT2 also catalyze the acetylation of the exocyclic hydroxyamino moiety. The acetylation reactions catalyzed by NAT1 and NAT2 can both activate and deactivate drugs and carcinogens depending upon the substrate and whether the catalysis is N-or O-acetylation. 3 Human NAT2 exhibits a well-established acetylation polymorphism that is associated with drug toxicities and various cancers following exposures to arylamines. [1] [2] [3] [4] Although less well-established, human NAT1 also exhibits genetic polymorphism and several studies have suggested that variant NAT1 genotypes are associated with susceptibility to a number of diseases including various cancers 2, 5 and birth defects. [6] [7] [8] [9] [10] The biological plausibility of these associations is based upon the role of human NAT1 in the metabolism of endogenous or exogenous agents. Single nucleotide polymorphisms (SNPs) in the human NAT1 coding region, present in less than 5% of Americans, Canadians and Europeans 11 but present in 25% of Lebanese 12 have been shown to modify risk of spina bifida. 10 Understanding the functional effects of SNPs in the NAT1 coding region is necessary to apply biological plausibility toward the associations observed with various diseases.
As summarized in Table 1 , SNPs in the 870 bp coding region of the NAT1 gene identify human NAT1 haplotypes.
13 NAT1*4 is defined as the reference haplotype with no SNPs. 13 Previous studies have explored some effects of SNPs in the NAT1 coding region following recombinant expression in bacteria [14] [15] [16] [17] [18] yeast 19 and HT-29 human colon adenocarinoma cells. 20 Phenotype designations of NAT1 coding region SNPs, as published in a review of arylamine N-acetyltransferases, 1 are summarized in Table 1 . Since functional mechanisms for phenotype expression of human NAT2 differ between prokaryotic and eukaryotic cells, 21 we investigated the functional effects of the NAT1 coding SNPs on N-and O-acetyltransferase catalytic activities, MichaelisMenten kinetic constants (K m and V max ), and steady-state expression levels of NAT1-specific mRNA and protein in mammalian cells.
Results

SNP effects on N-acetylation maximum velocities
N-acetyltransferase catalytic activities (maximum velocities) toward the NAT1-specific arylamine substrate p-aminobenzoic acid (PABA) were measured following recombinant expression of NAT1*4 and other NAT1 haplotypes possessing one or more SNPs in the NAT1 open reading frame ( Figure 1 ). C97T(R33stop), C559T(R187stop), C190T(R64W) and A752T (D251V) reduced PABA NAT1 catalytic activities (maximum velocities) below levels of detection. G560A(R187Q) significantly (Po0.01) decreased catalytic activity about 15-fold. In contrast, the combination of three SNPs (G445A(V149I), G459A(synonymous), T640G(S214A)) present in NAT1*11 significantly (Po0.05) increased PABA NAT1 catalytic activity about twofold compared to NAT1 4. T21G (synonymous), T402C (synonymous), A613G(M205V), T777C(synonymous), G781A(E261K) and A787G(I263V) did not significantly affect NAT1 catalytic activity. The effects of all SNPs on NAT1 maximum velocities were the same regardless of whether substrate (PABA) or cofactor (AcCoA) was varied in the presence of a fixed concentration of the co-substrate.
SNP effects on apparent K m Michaelis-Menten constants apparent K m and V max were determined by Eadie-Hofstee analyses. Compared to NAT1 4, G560A(R187Q) significantly (Po0.01) increased the apparent K m for PABA about sixfold whereas it did not affect apparent K m toward AcCoA (Figure 2) . None of the other SNPs significantly altered apparent K m to PABA or AcCoA for those variants in which catalytic activity was detectable ( Figure 2 ).
SNP effects on steady-state NAT1 mRNA levels The relative amount of NAT1 mRNA to endogenous b-actin mRNA was designated as 100% for NAT1*4. None of the SNPs in the NAT1 coding region significantly affected steady-state mRNA levels compared to NAT1*4 ( Figure 3 ).
SNP effects on NAT1 protein levels
Relative protein expression of NAT1 allozymes was quantified by densitometric analysis of western blots. Figure 4 shows two representative western blots for transient expression of NAT1 protein in COS-1 cells. The two nonsense SNPs (C97T and C559T) resulted in truncated proteins that were not detected by the NAT1 antibody. After normalization to endogenous a-tubulin, C190T(R64W) and A752T(D251V) caused large reductions in protein expression (50-and 40-folds, respectively). G560A significantly decreased (Po0.01) protein levels about fourfold. In contrast, the combination of three SNPs (G445A(V149I), G459A(synonymous), T640G(S214A)) present in NAT1*11 slightly (1.8-fold) but significantly (Po0.01) increased NAT1 protein level compared to NAT1*4. SNP effects on NAT1 protein levels correlated very highly (r 2 ¼ 0.96) with SNP effects on N-acetyltransferase maximum velocities.
SNP effects on O-acetylation catalytic activity N-hydroxy-2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (N-OH-PhIP) O-acetyltransferase catalytic activities were measured following recombinant expression of NAT1*4 and other NAT1 haplotypes possessing one or more ). Phenotypes as recently reviewed.
SNPs in the NAT1 open reading frame. As shown in Figure 5 , C97T(R33stop), C559T(R187stop), C190T(R64W) and A752T (D251V) reduced N-OH-PhIP O-acetyltransferase activity below detection. G560A(R187Q) significantly (Po0.01) decreased N-OH-PhIP O-acetyltransferase catalytic activity about 15-fold. None of the other SNPs or SNP combinations significantly affected N-OH-PhIP O-acetyltransferase activity although the combination of three SNPs (G445A(V149I), G459A(synonymous), T640G(S214A)) present in NAT1*11 increased N-OH-PhIP O-acetyltransferase catalytic activity 1.7-fold.
Discussion
The interpretation of past, present and future studies investigating a possible role of NAT1 genetic polymorphism with diseases such as cancer or birth defects is dependent upon accuracy in translating genomic data (SNPs, haplotypes or genotypes) into functional phenotypes. Many of the NAT1 haplotypes that have been identified in human populations contain a single SNP in the 870 bp NAT1 coding region (Table 1) . Although the functional effects of SNPs in the promoter and other regions of the NAT1 gene may also affect phenotype, 22, 23 our investigation focused on the functional effects of the SNPs identified in the NAT1 coding region.
As summarized in Table 1 , collection of data from previous studies led to phenotype assignments of NAT1*4 and NAT1*11 as 'normal', NAT1*14B, NAT1*15, NAT1*17, NAT1*19 as 'slow', NAT1*21, NAT1*24, NAT1*25 as 'rapid' and NAT1*20, NAT1*23, NAT1*27 as 'unknown'. The results of our studies in mammalian cells suggest substantial changes in these phenotype assignments as summarized in Table 2 . Our results confirm the previous assignment of ; CD11: SNPs in NAT1*11 coding region (G445A, G459A, T640G). Activity for each variant allozymes was compared to reference NAT1 4 catalytic activity by one-way ANOVA followed by Dunnett's post-test. *Significantly lower than NAT1 4 (Po0.01); **significantly greater than NAT1 4 (Po0.05). PABA N-acetyltransferase catalytic activities for C97T, C190T, C559T and A752T were too low (o0.05 nmol min À1 per mg) to determine V max . ). mRNA levels were tested for significant differences from reference (NAT1*4) by one-way ANOVA. No significant differences in mRNA level were observed.
NAT1*14B, NAT1*15, NAT1*17 and NAT1*19 as slow acetylators since the SNPs associated with these NAT1 haplotypes resulted in substantial and significant decreases in NAT1 protein level and both N-and O-acetyltransferase catalytic activities. In contrast, our results do not confirm assignments of NAT1*21, NAT1*24, NAT1*25 as 'rapid' acetylators since the SNPs associated with these NAT1 haplotypes did not significantly affect NAT1 protein level nor N-or O-acetyltransferase catalytic activities. Our results provide clarification regarding the 'unknown' phenotypes of NAT1*20, NAT1*23, NAT1*27 since our results show that the SNPs associated with these NAT1 haplotypes also did not significantly affect NAT1 protein level nor N-or O-acetyltransferase catalytic activities.
Since T21G, T402C and A777G are each synonymous SNPs that do not alter protein sequence, it is not surprising that they did not significantly alter NAT1 protein or mRNA levels, K m , nor N-and O-acetyltransferase catalytic activities. However, since other studies have shown that a synonymous 'silent' SNP alters substrate specificity 24 and mRNA folding 25 or stability, 26 it is important to investigate whether or not the synonymous SNPs affect NAT1 protein or mRNA levels, K m , nor N-and O-acetyltransferase catalytic activities.
Our results suggest heterogeneity among the NAT1*14B, NAT1*15, NAT1*17 and NAT1*19 'slow' acetylator haplotypes.
Whereas C97T(R33stop), C559T(R187stop), C190T(R64W) and A752T (D251V) reduced both N-and O-acetyltransferase catalytic activities below levels of (G445A, G459A, T640G ). NAT1-specific protein levels for the variant allozymes was compared to NAT1 4 by one-way ANOVA followed by Dunnett's post-test. C97T and C559T decreased the protein to nondetectable (ND) levels. The NAT1 antibody did not detect the truncated NAT1 proteins from C97T(R33stop) and C559T(R187stop). **C190T and A752T significantly (Po0.01) reduced NAT1 protein level over 40-fold and G560A significantly (Po0.01) reduced NAT1 protein level fourfold. *CD11 significantly (Po0.05) increased the level of recombinant NAT1 protein level about twofold.
Functional effects of coding SNPs on human NAT1
Y Zhu and DW Hein detection, G560A(R187Q) present in NAT1*14B caused a more moderate but significant decrease in catalytic activity (about 15-fold compared to NAT1*4). NAT1 protein levels were significantly reduced among all the slow acetylator haplotypes but less for NAT1 14B than for NAT1 17 and NAT1 22. Previous studies investigating the effects of coding region SNPs in NAT1 20 and NAT2 21, 27 have shown the decreases in protein level reflect increased protein degradation. In particular, the C190T(R64T) SNP also present in human NAT2 results in substantial reductions in NAT2 protein level and both N-and O-acetyltransferase catalytic activities, but no changes in mRNA or substrate affinity following recombinant expression in yeast, 28 results that precisely mimic the effects of this SNP on NAT1 reported here. Similar conclusions derive from site-directed mutagenesis of Arg64 in both human NAT1 and NAT2 followed by recombinant expression in bacteria.
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A recently study showed that NAT1*14, NAT1*15, NAT1*17 and NAT1*22 are associated with slow acetylator phenotypes because they encode proteins that are rapidly degraded within the cell and a common feature of these proteins is their inability to be acetylated by AcCoA, resulting in ubiquitination and rapid degradation by the 26 S proteasome. 20 Among the 'slow' acetylator haplotypes, both N-and O-acetyltransferase activities were detectable only for NAT1 14B and thus apparent K m s could only be The NAT1 antibody does not detect the truncated NAT1 protein.
Functional effects of coding SNPs on human NAT1
Y Zhu and DW Hein determined for NAT1 14B among the slow acetylator haplotypes. In addition to the decrease in protein level, G560A(R187Q) present in NAT1*14B also significantly increased apparent K m for PABA. This finding confirms previous results obtained following recombinant expression of human NAT1*14B in bacteria 15 and in human whole blood lysates.
17 G560A(R187Q) present in NAT1*14B and C190T(R64W) present in NAT1*17 are associated with reduced N-acetyltransferase activities 16, 20 and protein level 20 in peripheral blood mononuclear cells. Both also reduced N-acetyltransferase catalytic activity following recombinant expression in bacteria. 17, 18 An individual homozygous for C559T(R187stop) present in NAT1*15 showed undetectable N-acetyltransferase activity in human blood lysates 30 and recombinant expression of NAT1*15 in bacteria resulted in complete lack of N-acetyltransferase catalytic activity. 17 It should be noted that changes in K m may differ with substrate. Thus, changes in K m toward PABA will not necessarily generalize to other or all NAT1 substrates.
Since yeast is a eukaryotic cell, it is perhaps not surprising that the results of the present investigation following recombinant expression in COS-1 cells most closely mimic those previously reported following recombinant expression in yeast cells. 19 Although the lack of effects of any NAT1 coding region SNP on steady-state mRNA levels was reported in yeast, 19 the previous study measured mRNA via northern blots and was therefore less quantitative that PCR-based measurements employed in the present study. Following recombinant expression in bacteria, one study reported that G781A(E261K) present in NAT1*24 caused a small increase in N-acetyltransferase catalytic activity 18 whereas one study following recombinant expression in yeast reported that it caused a small decrease in O-acetyltransferase but had no significant effect on N-acetyltransferase activity. 19 In the present study, G781A(E261K) present in NAT1*24 did not significantly effect N-or O-acetyltransferase catalytic activity.
The combination of three SNPs (G445A(V149I), G459A (synonymous), T640G(S214A)) present in NAT1*11 slightly increased NAT1 protein level, and both N-and O-acetyltransferase catalytic activities. The increases in protein level and PABA N-acetyltransferase activities were significant (Po0.05). This result confirms findings following recombinant expression in bacteria 14 but not yeast. 19 Since coding region SNPs can affect degradation of NAT2 protein, 21, 27 it is possible that one or more of these SNPs in the NAT1 coding region reduces protein degradation resulting in slightly higher steady-state levels of NAT1 protein levels and hence catalytic activity. In addition to the coding region polymorphisms, NAT1*11 also has SNPs and nucleotide deletions both upstream and downstream of the open reading frame. Thus, assignment of phenotype for the NAT1*11 haplotype must also consider the effects of these polymorphisms that were not investigated in this study. One study that investigated the SNPs in the coding and 3 0 -noncoding exons of human NAT1*11 found that the combination of these SNPs did not significantly alter NAT1 protein levels or N-acetyltransferase catalytic activity. 31 Studies in human blood cells found that carriers of the NAT1*11 haplotype have equivalent N-acetyltransferase activities to carriers of NAT1*4, 32 whereas studies in human leukocytes found that carriers of the NAT1*11 haplotype had slightly but significantly lower N-acetyltransferase catalytic activity compared to carriers of NAT1*4.
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In summary, C97T(R33stop), C190T(R64W), C559T (R187stop) and A752T(D251V) each reduced NAT1 protein level and/or N-and O-acetyltransferase catalytic activities to levels below detection. G560A(R187Q) substantially and significantly reduced NAT1 protein level and catalytic activities and significantly increased substrate K m . The G445A(V149I), G459A(synonymous) and T640G(S214A) haplotype present in NAT1*11 significantly (Po0.05) increased NAT1 protein level and catalytic activity. Neither T21G(synonymous), T402C(synonymous), A613G(M205V), T777C(synonymous), G781A(E261K) or A787G(I263V) significantly affected K m , catalytic activity or protein level. None of the SNPs significantly affected steady-state levels of mRNA. SNP effects on both N-and O-acetyltransferase catalytic activities correlated very highly (r 2 ¼ 0.96) with changes in protein level, consistent with previous studies showing that the SNPs alter protein degradation. 20 These results also suggest heterogeneity among slow NAT1 acetylator phenotypes.
Materials and methods
Vector construction
The coding region of human NAT1*4 was amplified by PCR using plasmid pESP-3 possessing NAT1*4 coding region as template, 19 200 nM forward (5 0 -ACTGGTACCATGGACATT GAA-3 0 ; first Met codon is bolded and KpnI site underlined) and reverse (5 0 -GCCGGAATTCTTATTCTAAATAGTA-3 0 ; nucleotide 879 is bolded and EcoRI site underlined) primers, 200 mM each dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 in final volume of 50 ml. The PCR cycling parameters were 94 1C for 5 min, 30 cycles of 94 1C for 30 s, 55 1C for 30 s, 72 1C for 1 min, followed by additional extension for 8 min at 72 1C. The 889 base pair NAT1 PCR product (120 ng) and 60 ng linear vector pCR3.1 (Invitrogen Life Technology, Carlsbad, CA, USA) were ligated overnight at 15 1C with T4 DNA Ligase (New England Biolabs Inc., Beverly, MA, USA). Positive colonies were confirmed by automated DNA sequencing. This pCR3.1 NAT1*4-vector was used for the construction of other vectors. The plasmids carrying NAT1 SNPs T21G, C97T, C190T, T402C, C559T, G560A, A613G, A752T, T777C, G781A or A787G, or the three-SNP haplotype G445A, G459A, T640A and the basic construction (pCR3.1 NAT1*4-vector) were digested with HindIII, and the SNP-containing fragment and linear NAT1*4-vector were ligated using T4 DNA Ligase. Subsequently, vectors pCR3.1 possessing coding region NAT1 SNP(s) were confirmed by automated DNA sequencing.
Cell culture and transfection COS-1 cells (SV40-transformed African green monkey kidney cells) were purchased from American Type Culture Collection (Manassas, VA, USA). The COS-1 cells were routinely cultured in Dulbecco's modified eagle's medium, supplemented with 4.5 g l À1 glucose, 10% fetal bovine serum, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, and 4 mM L-glutamine. The cells were maintained at 37 1C with 10% CO 2 and subcultured every 2 or 3 days. Using Lipofectamine and Plus reagent, 10 mg each NAT1 SNPcontaining vector pCR3.1 and 80 ng pCMV SPORT-bgal (Invitrogen) plasmid were co-transfected into 2.2 million cells in 10 cm plates (90% confluence). The cells were harvested 48 h after transfection.
Cell lysate preparation
Transfected cells were removed from plates and washed with ice-cold phosphate-buffered saline, and pelleted by centrifugation. Cell pellets were disrupted in lysis buffer (20 mM sodium phosphate, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 10 mM phenylmethanesulfonyl fluoride, 10 mM leupetin, 1 mM pepstatin A, 4 mM aprotinin, 2 mg ml À1 bovine serum albumin) by sonication on ice for 15 s three times at 10 s intervals. Cell debris was precipitated at 15 000 r.p.m for 15 min at 4 1C.
b-Galacosidase activity assays
To account for possible differences in transfection efficiency between transfections, the COS-1 cell lysates were assayed for b-galacosidase activity with O-nitrophenyl b-D-galactopyranoside as substrate as described previously.
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N-acetyltransferase assays Cell lysates containing transiently expressed NAT1 allozymes were assayed for N-acetyltransferase activity using the NAT1-selective substrate PABA using modifications of procedures described previously 33 Cell lysates were diluted to ensure no more than 5% substrate converted to product. Reactions were performed at 37 1C for 5 min and terminated by adding 20 ml 1 M perchloric acid. The substrate PABA and product N-acetyl-PABA were separated and quantitated with high performance liquid chromatography (HPLC) on System Gold (Becker Coulter Inc., Fullerton, CA, USA). At a flow rate of 2 ml min À1 , a gradient was initiated with a hold of 96% aqueous (20 mM sodium perchlorate, pH 2.5): 4% acetonitrile for 3 min, changed to 88% aqueous: 12% acetonitrile over 2 min, followed by a second hold for 3 min, back to 96% aqueous: 4% acetonitrile over 1 min and concluded with a third hold for 3 min. Under these conditions, PABA and N-acetyl-PABA eluted at 2.5 and 7.5 min, respectively, and were quantified by absorbance at 280 nm. Negative controls substituted water for AcCoA or empty vector-transfected COS-1 cell lysate. Protein levels were determined by Bradford assay using Bio-Rad protein assay kit (Bio-Rad laboratories Inc., Hercules, CA, USA). Activities were normalized to b-galacosidase activities determined as described above.
Determination of apparent K m and V max for PABA and AcCoA The kinetic parameters K m and V max for PABA and cofactor AcCoA were determined. PABA N-acetyltransferase assays were performed as described above at a range of PABA concentrations (25-1000 mM) and a fixed AcCoA concentration of 1000 mM. PABA N-acetyltransferase catalytic activity determinations were also conducted over the range of AcCoA concentrations (25-3000 mM) at a fixed PABA concentration of 750 mM. The apparent K m and V max constants were calculated using linear regression of Eadie-Hofstee plots.
Quantitation of steady-state level of NAT1 mRNA
The mRNA level for each NAT1 SNP was determined with two-step quantitative real-time PCR. The total RNA was extracted from cells, and reversely transcribed into cDNA and then quantified by TaqMan gene-specific quantification. Total RNA from COS-1 cells was extracted using RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA). Crude RNA products were treated with Turbo-DNase (Ambion Inc., Austin, TX, USA) to remove DNA. DNA-free total RNA from transient transfected cells was used for reverse transcription. 
Quantitation of steady-state level of NAT1 protein level
Total protein concentration of transfected cell lysates 48 h after transfection was quantified with Bradford assay using Bio-Rad protein assay kit (Bio-Rad). Cell lysates were separated on 12% SDS-PAGE gel (Tris-Glycine Gel Novex; Invitrogen), and then transferred to Immuno-PVDF membrane (Bio-Rad). The NAT1 bands were detected by incubation with anti-NAT1 purified rabbit polyclonal antibody (kindly provided by Dr Edith Sim, Oxford University, UK) in 1:2000 dilutions, and then with peroxidase-conjugated antirabbit secondary antibody (GE Health Care, Piscataway, NJ, USA) at 1:16 000 dilution, and visualized ECL plus western blot detection system (GE Health Care). The membrane was stripped in stripping buffer (100 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM b-mercaptoethanol). Subsequently, the stripped membrane was incubated with monoclonal antihuman a-tubulin produced in mouse (Sigma) at 1:2000 dilution, and then with secondary antibody peroxidaseconjugated anti-mouse immunoglobulin G produced in goat (GE Health Care) at 1:40 000 dilution. The immunoreactive a-tubulin was detected using ECL plus western blotting detection system (GE Health Care). The quantity of NAT1 protein and a-tubulin were determined by densitometric analysis.
O-acetyltransferase activity assay N-OH-PhIP O-acetyltransferase activity of NAT1 allozymes was determined by HPLC as previously described. 33 Briefly, cell lysates were suitably diluted to ensure that consumption of N-OH-PhIP in the reaction did not exceed 5%. The reactions were initiated by addition of N-OH-PhIP to final concentration of 100 mM in the presence of 1 mM AcCoA. Negative control reactions substituted water for AcCoA. Reactions were carried out at 37 1C for 40 min. Protein levels were determined by Bradford assay using Bio-Rad protein assay kit (Bio-Rad). Activities were normalized to b-galacosidase activities determined as described above.
Statistical analyses
Differences between reference (NAT1 4) and variant NAT1 haplotypes possessing one or more SNPs were tested for significance using one-way ANOVA followed by Dunnett's post-test. Differences were considered significant at Po0.05.
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